Please assess the completion status of the following clinical trial:

Trial Title: A Phase I Study of MK-2206 in Combination With Standard Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors (MK-2206-003)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria :~* Participants must have locally advanced or metastatic solid tumors.~* Participant is male or female greater than or equal to 18 years of age.~* Participant must have a performance status less than or equal to 1 on the Eastern Cooperative Oncology Group (ECOG) Performance Scale~* Female participants of childbearing potential has a negative serum or urine pregnancy test within 72 hours prior to receiving the first dose of study medication.~* Participants in the MK-2206 + carboplatin/paclitaxel and MK-2206 + docetaxel treatment arms will be limited to no more than 3 prior cytotoxic therapies for metastatic or recurrent diseases.~* Participant is able to swallow capsules and has no surgical or anatomical condition that will prevent the Participant from swallowing.~Exclusion Criteria:~* Participant has had chemotherapy, radiotherapy or biological therapy within 4 weeks.~* Participants must be least 4 weeks post-surgery and do not expect major surgery in the study duration.~* Participant is currently participating or has participated in a study with an investigational compound or device within 30 days.~* Participant has known active central nervous system (CNS) metastases and/or carcinomatous meningitis.~* Participant with a primary central nervous system tumor.~* Participant has known hypersensitivity to the components of study drug.~* Participant has a history or current evidence of heart disease.~* Participant has evidence of clinically significant bradycardia (slow heart rate).~* Participant has uncontrolled high blood pressure.~* Participant at significant risk for hypokalemia (low potassium levels).~* Participant is a known diabetic~* Participant has known psychiatric or substance abuse disorders.~* Participant is a user of illicit drugs.~* Participant is pregnant or breastfeeding.~* Participant is Human Immunodeficiency Virus (HIV) positive.~* Participant has known history of Hepatitis B or C or active Hepatitis A.~* Participant has symptomatic ascites or pleural effusion.~* Participant is receiving treatment with oral corticosteroids.~* Participant is using a potent cytochrome P(450) 3A4 (CYP3A4) inhibitor or inducer.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MK-2206 + carboplatin + paclitaxel (Type: EXPERIMENTAL): MK-2206 combined with carboplatin and paclitaxel
- MK-2206 + docetaxel (Type: EXPERIMENTAL): MK-2206 combined with docetaxel plus pretreatment with a corticosteroid
- MK-2206 + erlotinib (Type: EXPERIMENTAL): MK-2206 combined with erlotinib

Based on this trial design, predict the completion outcome and termination type (if applicable).